Autologous Cd34+ Cells Transduced With Tns9.3.55
Severe Combined Immunodeficiency
National Institute of Allergy and Infectious Diseases (NIAID)unclassifiedPhase 1/2Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 95/ 100
Competitive context
14 Active assets in the Severe Combined Immunodeficiency cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2/3 | BB |
Nivestim National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | BB |
Alemtuzumab Washington University School of Medicine | Phase 2/3 | BB |
Cyclophosphamide St. Jude Children's Research Hospital | Phase 2/3 | BB |
Busulfanum National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2/3 | BB |
View all 30 →
Same molecule, other indications
Autologous Cd34+ Cells Transduced With Tns9.3.55 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →